Top

10-05-2024 | Acute Respiratory Distress-Syndrome | Case Report

A case of acute lung injury in a peripheral blood stem cell donor mobilized with pegylated recombinant human granulocyte colony-stimulating factor

Authors: Lin Liu, Ding-song Zhang, Xue-juan Zhang, Zhong-zheng Zheng, San-bin Wang

Published in: International Journal of Hematology

Abstract

Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) has been introduced for the mobilization of peripheral blood stem cells (PBSCs). However, no cases of acute lung injury (ALI) in healthy donors have been reported, and the underlying mechanisms remain poorly understood. We first reported a case of ALI caused by PEG-rhG-CSF in a healthy Chinese donor, characterized by hemoptysis, hypoxemia, and patchy shadows. Ultimately, hormone administration, planned PBSC collection, leukocyte debridement, and planned PBSC collection resulted in active control of the donor's ALI. The donor's symptoms improved without any adverse effects, and the PBSC collection proceeded without incident. Over time, the lung lesion was gradually absorbed and eventually returned to normal. PEG-rhG-CSF may contribute to ALI in healthy donors via mechanisms involving neutrophil aggregation, adhesion, and the release of inflammatory mediators in the lung. This case report examines the clinical manifestations, treatment, and mechanism of lung injury induced by PEG-rhG-CSF-mobilized PBSCs.

Miskiewicz-Migon I, Miskiewicz-Bujna J, Rosa M, Kubica-Cielinska A, Bladowska J, Janczar S, et al. Severe, reversible acute lung injury during autologous hematopoietic stem cell mobilization after filgrastim in a child with neuroblastoma: a case report. Transplant Proc. 2020;52(9):2849–53. https://doi.org/10.1016/j.transproceed.2020.06.027.CrossRefPubMed

Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rg-csf). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs. 1991;42(2):300–30. https://doi.org/10.2165/00003495-199142020-00009.CrossRefPubMed

Caselli D, Cesaro S, Arico M. Biosimilars in the management of neutropenia: focus on filgrastim. Biologics. 2016;10:17–22. https://doi.org/10.2147/BTT.S73580.CrossRefPubMedPubMedCentral

Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N, et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica. 2005;90(3):R10.

Yamamoto K, Doki N, Senoo Y, Najima Y, Kobayashi T, Kakihana K, et al. Severe hypoxemia in a healthy donor for allogeneic hematopoietic stem cell transplantation after only the first administration of granulocyte-colony stimulating factor. Transfus Med Hemother. 2016;43(6):433–5. https://doi.org/10.1159/000446814.CrossRefPubMedPubMedCentral

Arvedson T, Kelly OJ, Yang B. Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs. 2015;29(3):185–98. https://doi.org/10.1007/s40259-015-0127-4.CrossRefPubMedPubMedCentral

Kido BYAA. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;5(50):295–306.

Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, et al. phase i clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor. Ai Zheng. 2006;25(4):495–500.PubMed

Yukawa K, Mokuda S, Yoshida Y, Hirata S, Sugiyama E. Large-vessel vasculitis associated with pegylated granulocyte-colony stimulating factor. Neth J Med. 2019;77(6):224–6.PubMed

10.

Do BH, Kang HJ, Song JA, Nguyen MT, Park S, Yoo J, et al. Granulocyte colony-stimulating factor (gcsf) fused with fc domain produced from E. Coli is less effective than polyethylene glycol-conjugated gcsf. Sci Rep. 2017;7(1):6480. https://doi.org/10.1038/s41598-017-06726-7.CrossRefPubMedPubMedCentral

11.

Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-csf is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17(4):413–23. https://doi.org/10.1016/s1074-7613(02)00424-7.CrossRefPubMed

12.

Szade A, Szade K, Nowak WN, Bukowska-Strakova K, Muchova L, Gonka M, et al. Cobalt protoporphyrin ix increases endogenous g-csf and mobilizes hsc and granulocytes to the blood. Embo Mol Med. 2019;11(12):e9571. https://doi.org/10.15252/emmm.201809571.CrossRef

13.

Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw P, McInnes IB, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in covid-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020;8(8):822–30. https://doi.org/10.1016/S2213-2600(20)30267-8.CrossRefPubMedPubMedCentral

14.

Hatfield KJ, Melve GK, Bruserud O. Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors. Metabolomics. 2017;13(1):2. https://doi.org/10.1007/s11306-016-1139-x.CrossRefPubMed

15.

Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26(5):545–58. https://doi.org/10.1016/j.cytogfr.2015.07.006.CrossRefPubMed

16.

Bendall LJ, Bradstock KF. G-csf: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25(4):355–67. https://doi.org/10.1016/j.cytogfr.2014.07.011.CrossRefPubMed

17.

Tvedt T, Melve GK, Tsykunova G, Ahmed AB, Brenner AK, Bruserud O. Immunological heterogeneity of healthy peripheral blood stem cell donors-effects of granulocyte colony-stimulating factor on inflammatory responses. Int J Mol Sci. 2018;19(10):2886. https://doi.org/10.3390/ijms19102886.CrossRefPubMedPubMedCentral

18.

Bruserud O, Melve GK, Gedde-Dahl T, Tvedt T. Immunological heterogeneity of healthy peripheral blood stem cell donors—preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation. Expert Rev Hematol. 2018;11(10):757–9. https://doi.org/10.1080/17474086.2018.1511420.CrossRefPubMed

19.

Melve GK, Ersvaer E, Eide GE, Kristoffersen EK, Bruserud O. Peripheral blood stem cell mobilization in healthy donors by granulocyte colony-stimulating factor causes preferential mobilization of lymphocyte subsets. Front Immunol. 2018;9:845. https://doi.org/10.3389/fimmu.2018.00845.CrossRefPubMedPubMedCentral

20.

Ilhan C, Suyani E, Sucak GT, Pasaoglu OT, Aki SZ, Pasaoglu H. Inflammatory markers, oxidative stress, and antioxidant capacity in healthy allo-hsct donors during hematopoietic stem cell mobilization. J Clin Apher. 2015;30(4):197–203. https://doi.org/10.1002/jca.21361.CrossRefPubMed

21.

Fidyk W, Mitrus I, Ciomber A, Smagur A, Chwieduk A, Glowala-Kosinska M, et al. Evaluation of proinflammatory and immunosuppressive cytokines in blood and bone marrow of healthy hematopoietic stem cell donors. Cytokine. 2018;102:181–6. https://doi.org/10.1016/j.cyto.2017.09.001.CrossRefPubMed

Title: A case of acute lung injury in a peripheral blood stem cell donor mobilized with pegylated recombinant human granulocyte colony-stimulating factor
Authors: Lin Liu
Ding-song Zhang
Xue-juan Zhang
Zhong-zheng Zheng
San-bin Wang
Publication date: 10-05-2024
Publisher: Springer Nature Singapore
Keywords: Acute Respiratory Distress-Syndrome
Hemoptysis
Hemoptysis
Filgrastim
Filgrastim
Published in: International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-024-03779-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer